Sign in to view content

Treatment Response to Antioxidant Supplementation Based on CFH and ARMS2Â Genetic Risk Allele Number in AREDS Patients With No AMD at Baseline

Carl C. Awh, MD, FASRS

Video
Published 2016

Related

Pigmented Splotch
Tara A. McCannel, MD, PhD
Annual Meeting Talks
2016
“Real World” U.S. Outcomes of Anti-VEGF Therapy in Neovascular AMD: Risk of Vision Loss is Greatest in Patients with Better Baseline Visual Acuity
Thomas A. Ciulla, MD, MBA, FASRS
Annual Meeting Talks
2016
The Updated AREDS Simplified Severity Scale for Age-Related Macular Degeneration, Incorporating Reticular Pseudodrusen
Tiarnan D Keenan, BM BCh, PhD
Updates from the Field
2024

Category: AMD-Non-Neovascular

See more